Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|April 13, 2022
Daily Medication Pearl: Maralixibat (Livmarli)
Author(s)Saro Arakelians, PharmD
Maralixibat (Livmarli) is an ileal bile acid transporter inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
Advertisement
Medication Pearl of the Day: Maralixibat (Livmarli)
Indication: Maralixibat (Livmarli) is an ileal bile acid transporter (IBAT) inhibitor indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.
Insight:
- Dosing:The recommended dosage is 380 mcg/kg once daily, taken 30 minutes before the first meal of the day.
- Dosage forms: Oral solution 9.5 mg of maralixibat per mL.
- Adverse events: Most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding, and bone fractures.
- Mechanism of action: Maralixibat is a reversible inhibitor of IBAT. It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum.
- Manufacturer: Mirum Pharmaceuticals
Source
Advertisement
Related to this article
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, while sulfonylureas signaled faster decline without it.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
5